Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding
<p>Abstract</p> <p>Background</p> <p>For patients with a normal coagulation system, who experience serious bleeding, sound evidence for recombinant activated factor VII (rFVIIa) as an effective haemostatic agent is only scarcely available so far from controlled clinical...
Main Authors: | Wiedermann CJ, Pechlaner C, Eller P |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2006-01-01
|
Series: | Thrombosis Journal |
Online Access: | http://www.thrombosisjournal.com/content/4/1/1 |
Similar Items
-
The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
by: de Lourdes Herrera Maria, et al.
Published: (2010-05-01) -
Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation
by: Allison L Hollis, et al.
Published: (2016-01-01) -
Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery
by: Aly Makram Habib, et al.
Published: (2016-10-01) -
A Critical Reappraisal of Gastrointestinal Complications of Allogeneic Bone Marrow Transplantation
by: Gary J. Schiller, et al.
Published: (1992-03-01) -
Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients
by: AlGahtani Farjah, et al.
Published: (2010-01-01)